Anti-Lysine, Acetylated (Acetyl-Lysine) Monoclonal Antibody

Anti-Lysine, Acetylated (Acetyl-Lysine) Monoclonal Antibody

Cat# L9058-02C-100ul

Size : 100ul

Brand : US Biological

Request more information



L9058-02C Lysine, Acetylated (Acetyl-Lysine)

Clone Type
Polyclonal
Host
rabbit
Isotype
IgG
Grade
Purified
Applications
ChIP E IP WB
Crossreactivity
Bo Ce Ca Ch Hm Hu Mk Mo Po Rt Xe Ze
Shipping Temp
Blue Ice
Storage Temp
-20°C

Acetylation of lysine, like phosphorylation of serine, threonine or tyrosine, is an important reversible modification controlling protein activity. The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (1). Signaling resulting in acetylation/ deacetylation of histones, transcription factors and other proteins affects a diverse array of cellular processes including chromatin structure and gene activity, cell growth, differentiation and apoptosis (2-6). Recent proteomic surveys suggest that acetylation of lysine residues may be a widespread and important form of posttranslational protein modification that affects thousands of proteins involved in control of cell cycle and metabolism, longevity, actin|polymerization and nuclear transport (7,8). The regulation of protein acetylation status is Impaired in the pathologies of cancer and polyglutamine diseases (9), and HDACs have|become promising targets for anti-cancer drugs currently in development (10). ||Applications: |Suitable for use in ELISA, Western Blot and Immunoprecipitation. Other applications not tested.||Recommended Dilution:|ELISA-Peptide: 1:1000|Western Blot: 1:1000 Incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.|Immunoprecipitation: 1:100|Chromatin IP: 1:50|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Product Type: Mab|Isotype: IgG|Clone No: 11C1044(Ac-K2-100)|Host: rabbit|Source: human|Concentration: Not determined|Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, <0.02% sodium azide, 50% glycerol.|Purity: Purified|Immunogen: Synthetic peptide corresponding to the Acetylated-Lysine library.|Specificity: Recognizes acetylated lysine in a wide range of sequence contexts. Species Crossreactivity: human, mouse, rat, hamster, monkey, mink, chicken, D. melanogaster, xenopus, zebrafish, bovine, canine, porcine, S. cerevisiae, C. elegans and equine.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to the Acetylated-Lysine library.
Form
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, <0.02% sodium azide, 50% glycerol.
Purity
Purified
Specificity
Recognizes acetylated lysine in a wide range of sequence contexts. Species Crossreactivity: human, mouse, rat, hamster, monkey, mink, chicken, D. melanogaster, xenopus, zebrafish, bovine, canine, porcine, S. cerevisiae, C. elegans and equine.
References
1. Hassig, C.A. and Schreiber, S.L. (1997) Curr Opin Chem Biol 1, 300-8. 2. Allfrey, V.G. et al. (1964) Proc Natl Acad Sci USA 51, 786-94. 3. Liu, L. et al. (1999) Mol Cell Biol 19, 1202-9 .4. Boyes, J. et al. (1998) Nature 396, 594-8. 5. Polevoda, B. and Sherman, F. (2002) Genome Biol 3, reviews0006. 6. Yoshida, M. et al. (2003) Prog Cell Cycle Res 5, 269-78. 7. Kim, S.C. et al. (2006) Mol Cell 23, 607-18. 8. Choudhary, C. et al. (2009) Science 325, 834-40. 9. Hughes, R.E. (2002) Curr Biol 12, R141-3. 10. Vigushin, D.M. and Coombes, R.C. (2004) Curr Cancer Drug Targets 4, 205-18.